Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis

Autoimmunity Reviews

Volumn 10, Issue 5, 2011, Pages 241-243

  Galluccio, Felice ^a   Matucci Cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Digital ulcers; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; NEUROTRANSMITTER; NIFEDIPINE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PROSTACYCLIN; PROSTAGLANDIN E1; SILDENAFIL; SITAXSENTAN; THROMBOXANE; UNIPROST;

BLOOD VESSEL TONE; CARDIOTOXICITY; CLINICAL FEATURE; CONTINUOUS INFUSION; DIGITAL ULCER; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROVASCULATURE; NEPHROTOXICITY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; ULCER; VASCULAR DISEASE; VASODILATATION; VASOSPASM;

AUTOANTIBODIES; COLD TEMPERATURE; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; FIBROSIS; HUMANS; IMMUNE SYSTEM PHENOMENA; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; SKIN ULCER; SPASM; ULNAR ARTERY; VASOCONSTRICTION;

EID: 79952038069     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.09.008     Document Type: Review

References (40)

1. Guiducci S., Giacomelli R., Matucci-Cerinic M. Vascular complications of scleroderma. Autoimmun Rev 2007, 6:520-523.
2. Hasegawa M., Nagai Y., Tamura A., Ishikawa O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 2006, 155:1159-1164.
3. Geyer Matthias, Müller-Ladner Ulf The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol Jan 20 2010, [Epub ahead of print].
4. Kahaleh B.M. Vascular involvement in systemic sclerosis. Clin Exp Rheumatol 2004, 22(3 Suppl 33):S19-S23.
5. Cutolo M., Grassi W., Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003, 48:3023-3030.
6. Abraham D.J., Krieg T., Distler J., Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009, 48. [Suppl 3:iii3-7].
7. Hebbar M., Peyrat J.P., Hornez L., Hatron P.Y., Hachulla E., Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000, 43:889-893.
8. Distler O., Del Rosso A., Giacomelli R., et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11.
9. LeRoy E.C., Medsger T.A. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992, 10:485-488.
10. Herrick A.L. Pathogenesis of Raynaud's phenomenon. Rheumatology 2005, 44:587-596.
11. Hachulla E., Clerson P., Launay D., Lambert M., Morell-Dubois S., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007, 34:2423-2430.
12. Walker U.A., Tyndall A., Czirják L., Denton C., Farge-Bancel D., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
13. Mouthon L., Mestre-Stanislas C., Bérezné A., Rannou F., Guilpain P., et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010, 69:214-217.
14. Korn J.H. Scleroderma: a treatable disease. Cleve Clin J Med 2003, 70:954-968.
15. Nihtyanova S.I., Brough G.M., Black C.M., Denton C.P. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008, 67:120-123.
16. Denton C., Korn J. Digital ulceration and critical digital ischemia in scleroderma. Scleroderma Care Res 2003, 1:12-16.
17. Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford). 2010;49(7):1374-82.
18. Fraenkel L. Raynaud's phenomenon: epidemiology and risk factors. Curr Rheumatol Rep 2002, 4:123-128.
19. Chung L., Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006, 5:125-128.
20. Thompson A.E., Pope J.E. Calcium-channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology 2005, 44:145-150.
21. Rademaker M., Cooke E.D., Almond N.E., et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Br Med J 1989, 298:561-564.
22. Wigley F.M., Wise R.A., Seibold J.R., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994, 120:199-206.
23. Fiori G., Galluccio F., Braschi F., Amanzi L., Miniati I., et al. Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis. Clin Exp Rheumatol 2009, 27(3 Suppl 54):51-54.
24. Chung L., Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 2006, 54:880-882.
25. Biondi M.L., Marasini B., Bassani C., Agastoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med 1991, 324:1139-1140.
26. Yamane K., Miyauchi T., Suzuki N., et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992, 19:1566-1571.
27. Seibold J.R., Matucci-Cerinic M., Denton C.P., et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis 2006, 65(Suppl. II):90.
28. Black C., Denton C.P., Furst D.E., et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis - open label extension to a double-blind trial. Ann Rheum Dis 2006, 65(Suppl. II):384.
29. Korn J.H., Mayes M. Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985-3993.
30. Gholam P., Sehr T., Enk A., Hartmann M. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxsentan). Dermatology 2009, 219:171-173.
31. Fries R., Shariat K., von Wilmowsky H., Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005, 112:2980-2985.
32. Colglazier C., Sutej P., O'Rourke K. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 2005, 32:2440-2442.
33. Gore J., Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005, 64:1387.
34. Brueckner C.S., Becker M.O., Kroencke T., Huscher D., Scherer H.U., Worm, et al. Effect of Sildenafil on digital ulcers in systemic sclerosis - analysis from a single centre pilot study. Ann Rheum Dis 2009 Nov 8, [Epub ahead of print].
35. Abou-Raya A., Abou-Raya S., Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008, 35:1801-1808.
36. Kuwana M., Okazaki Y., Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol 2009, 19:530-535.
37. Bogoch E., Gross D. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005, 32:642-648.
38. Fregene A., Ditmars D., Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. J Hand Surg Am 2009, 34:446-452.
39. Nevskaya T., Ananieva L., Bykovskaia S., Eremin I., Karandashov E., et al. Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rheumatology (Oxford). 2009, 48:61-64.
40. Hama M, Kirino Y, Ueda A, Takeno M, Shirai A, Ohno S. Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells. Modern Rheumatol published on line February 19, 2010.